|
1
|
Giudice LC: Clinical practice.
Endometriosis. N Engl J Med. 362:2389–2398. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wei JJ, William J and Bulun S:
Endometriosis and ovarian cancer: A review of clinical, pathologic,
and molecular aspects. Int J Gynecol Pathol. 30:553–568.
2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Machida H, Matsuo K, Yamagami W, Ebina Y,
Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T and Mikami
M: Trends and characteristics of epithelial ovarian cancer in Japan
between 2002 and 2015: A JSGO-JSOG joint study. Gynecol Oncol.
153:589–596. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yamaguchi K, Mandai M, Toyokuni S,
Hamanishi J, Higuchi T, Takakura K and Fujii S: Contents of
endometriotic cysts, especially the high concentration of free
iron, are a possible cause of carcinogenesis in the cysts through
the iron-induced persistent oxidative stress. Clin Cancer Res.
14:32–40. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Van Langendonckt A, Casanas-Roux F and
Donnez J: Iron overload in the peritoneal cavity of women with
pelvic endometriosis. Fertil Steril. 78:712–718. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mandai M, Matsumura N, Baba T, Yamaguchi
K, Hamanishi J and Konishi I: Ovarian clear cell carcinoma as a
stress-responsive cancer: Influence of the microenvironment on the
carcinogenesis and cancer phenotype. Cancer Lett. 310:129–133.
2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kobayashi H: Potential scenarios leading
to ovarian cancer arising from endometriosis. Redox Rep.
21:119–126. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sampson JA: Endometrial carcinoma of the
ovary, arising in endometrial tissue in that organ. Arch Surg.
10:1–72. 1925.
|
|
9
|
Kobayashi H, Sumimoto K, Moniwa N, Imai M,
Takakura K, Kuromaki T, Morioka E, Arisawa K and Terao T: Risk of
developing ovarian cancer among women with ovarian endometrioma: A
cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 17:37–43.
2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yachida N, Yoshihara K, Yamaguchi M, Suda
K, Tamura R and Enomoto T: How does endometriosis lead to ovarian
cancer? The molecular mechanism of endometriosis-associated ovarian
cancer development. Cancers (Basel). 13(1439)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Murakami K, Kotani Y, Nakai H and
Matsumura N: Endometriosis-Associated ovarian cancer: The origin
and targeted therapy. Cancers (Basel). 12(1676)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Melin A, Sparén P, Persson I and Bergqvist
A: Endometriosis and the risk of cancer with special emphasis on
ovarian cancer. Hum Reprod. 21:1237–1242. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dixon-Suen SC, Webb PM, Wilson LF, Tuesley
K, Stewart LM and Jordan SJ: The association between hysterectomy
and ovarian cancer risk: A population-based record-linkage study. J
Natl Cancer Inst. 111:1097–1103. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
LaGrenade A and Silverberg SG: Ovarian
tumors associated with atypical endometriosis. Hum Pathol.
19:1080–1084. 1988.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Stern RC, Dash R, Bentley RC, Snyder MJ,
Haney AF and Robboy SJ: Malignancy in endometriosis: Frequency and
comparison of ovarian and extraovarian types. Int J Gynecol Pathol.
20:133–139. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kondi-Pafiti A, Papakonstantinou E,
Iavazzo C, Grigoriadis C, Salakos N and Gregoriou O:
Clinicopathological characteristics of ovarian carcinomas
associated with endometriosis. Arch Gynecol Obstet. 285:479–483.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fukunaga M, Nomura K, Ishikawa E and
Ushigome S: Ovarian atypical endometriosis: Its close association
with malignant epithelial tumours. Histopathology. 30:249–255.
1997.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Van Gorp T, Amant F, Neven P, Vergote I
and Moerman P: Endometriosis and the development of malignant
tumours of the pelvis. A review of literature. Best Pract Res Clin
Obstet Gynaecol. 18:349–371. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vercellini P, Cribiù FM, Del Gobbo A,
Carcangiu ML, Somigliana E and Bòsari S: The oncofetal protein
IMP3: A novel biomarker and triage tool for premalignant atypical
endometriotic lesions. Fertil Steril. 99:1974–1979. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Varga J, Reviczká A, Háková H, Švajdler P,
Rabajdová M and Ostró A: Predictive factors of endometriosis
progression into ovarian cancer. J Ovarian Res.
15(5)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dunselman GA, Vermeulen N, Becker C,
Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW,
Kiesel L, Nap A, et al: ESHRE guideline: Management of women with
endometriosis. Hum Reprod. 29:400–412. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Iwabuchi T, Yoshimoto C, Shigetomi H and
Kobayashi H: Oxidative stress and antioxidant defense in
endometriosis and its malignant transformation. Oxid Med Cell
Longev. 2015(848595)2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kobayashi H, Yamada Y, Kawahara N, Ogawa K
and Yoshimoto C: Integrating modern approaches to pathogenetic
concepts of malignant transformation of endometriosis. Oncol Rep.
41:1729–1738. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Akashi K, Nagashima Y, Tabata T and Oda H:
Immunochemical analysis of iron transporters and M2 macrophages in
ovarian endometrioma and clear cell adenocarcinoma. Mol Clin Oncol.
15(159)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Seidman JD: The presence of mucosal iron
in the fallopian tube supports the ‘incessant menstruation
hypothesis’ for ovarian carcinoma. Int J Gynecol Pathol.
32:454–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yamada Y, Shigetomi H, Onogi A, Haruta S,
Kawaguchi R, Yoshida S, Furukawa N, Nagai A, Tanase Y, Tsunemi T,
et al: Redox-active iron-induced oxidative stress in the
pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol
Cancer. 21:1200–1207. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Iwabuchi T, Yoshimoto C, Shigetomi H and
Kobayashi H: Cyst fluid hemoglobin species in endometriosis and its
malignant transformation: The role of metallobiology. Oncol Lett.
11:3384–3388. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yamaguchi K, Kitamura S, Furutake Y,
Murakami R, Yamanoi K, Taki M, Ukita M, Hamanishi J and Mandai M:
Acquired evolution of mitochondrial metabolism regulated by HNF1B
in ovarian clear cell carcinoma. Cancers (Basel).
13(2413)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kobayashi H, Imanaka S and Shigetomi H:
Revisiting therapeutic strategies for ovarian cancer by focusing on
redox homeostasis. Oncol Lett. 23(80)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Vercellini P, Crosignani P, Somigliana E,
Viganò P, Buggio L, Bolis G and Fedele L: The ‘incessant
menstruation’ hypothesis: A mechanistic ovarian cancer model with
implications for prevention. Hum Reprod. 26:2262–2273.
2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Defrère S, Van Langendonckt A, Vaesen S,
Jouret M, González Ramos R, Gonzalez D and Donnez J: Iron overload
enhances epithelial cell proliferation in endometriotic lesions
induced in a murine model. Hum Reprod. 21:2810–2816.
2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Toyokuni S: Iron as a target of
chemoprevention for longevity in humans. Free Radic Res.
45:906–917. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yoshimoto C, Iwabuchi T, Shigetomi H and
Kobayashi H: Cyst fluid iron-related compounds as useful markers to
distinguish malignant transformation from benign endometriotic
cysts. Cancer Biomark. 15:493–499. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nagayasu M, Imanaka S, Kimura M, Maruyama
S and Kobayashi H: Nonhormonal treatment for endometriosis focusing
on redox imbalance. Gynecol Obstet Invest. 86:1–12. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Turrens JF: Mitochondrial formation of
reactive oxygen species. J Physiol. 552(Pt 2):335–344.
2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
He L, He T, Farrar S, Ji L, Liu T and Ma
X: Antioxidants maintain cellular redox homeostasis by elimination
of reactive oxygen species. Cell Physiol Biochem. 44:532–553.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ota H, Igarashi S, Hatazawa J and Tanaka
T: Endometriosis and free radicals. Gynecol Obstet Invest. 48
(Suppl 1):S29–S35. 1999.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jana SK, Dutta M, Joshi M, Srivastava S,
Chakravarty B and Chaudhury K: 1H NMR based targeted metabolite
profiling for understanding the complex relationship connecting
oxidative stress with endometriosis. Biomed Res Int.
2013(329058)2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Singh AK, Chattopadhyay R, Chakravarty B
and Chaudhury K: Markers of oxidative stress in follicular fluid of
women with endometriosis and tubal infertility undergoing IVF.
Reprod Toxicol. 42:116–124. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Moon EJ and Giaccia A: Dual roles of NRF2
in tumor prevention and progression: Possible implications in
cancer treatment. Free Radic Biol Med. 79:292–299. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Vahid F and Davoodi SH: Nutritional
factors involved in the etiology of gastric cancer: A systematic
review. Nutr Cancer. 73:376–390. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Müller MF, Florian S, Pommer S, Osterhoff
M, Esworthy RS, Chu FF, Brigelius-Flohé R and Kipp AP: Deletion of
glutathione peroxidase-2 inhibits azoxymethane-induced colon cancer
development. PLoS One. 8(e72055)2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Fujimoto Y, Imanaka S, Yamada Y, Ogawa K,
Ito F, Kawahara N, Yoshimoto C and Kobayashi H: Comparison of redox
parameters in ovarian endometrioma and its malignant
transformation. Oncol Lett. 16:5257–5264. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Young VJ, Brown JK, Maybin J, Saunders PT,
Duncan WC and Horne AW: Transforming growth factor-β induced
Warburg-like metabolic reprogramming may underpin the development
of peritoneal endometriosis. J Clin Endocrinol Metab. 99:3450–3459.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Young VJ, Ahmad SF, Brown JK, Duncan WC
and Horne AW: ID2 mediates the transforming growth
factor-β1-induced Warburg-like effect seen in the peritoneum of
women with endometriosis. Mol Hum Reprod. 22:648–654.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Okamoto T, Mandai M, Matsumura N,
Yamaguchi K, Kondoh H, Amano Y, Baba T, Hamanishi J, Abiko K,
Kosaka K, et al: Hepatocyte nuclear factor-1β (HNF-1β) promotes
glucose uptake and glycolytic activity in ovarian clear cell
carcinoma. Mol Carcinog. 54:35–49. 2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kobayashi H, Shigetomi H and Imanaka S:
Nonhormonal therapy for endometriosis based on energy metabolism
regulation. Reprod Fertil. 2:C42–C57. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ying H, Kimmelman AC, Lyssiotis CA, Hua S,
Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff
JL, et al: Oncogenic Kras maintains pancreatic tumors through
regulation of anabolic glucose metabolism. Cell. 149:656–670.
2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Bhattacharya B, Low SH, Soh C, Kamal
Mustapa N, Beloueche-Babari M, Koh KX, Loh J and Soong R: Increased
drug resistance is associated with reduced glucose levels and an
enhanced glycolysis phenotype. Br J Pharmacol. 171:3255–3267.
2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zhou MY, Cheng ML, Huang T, Hu RH, Zou GL,
Li H, Zhang BF, Zhu JJ, Liu YM, Liu Y and Zhao XK: Transforming
growth factor beta-1 upregulates glucose transporter 1 and
glycolysis through canonical and noncanonical pathways in hepatic
stellate cells. World J Gastroenterol. 27:6908–6926.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kitamura S, Yamaguchi K, Murakami R,
Furutake Y, Higasa K, Abiko K, Hamanishi J, Baba T, Matsumura N and
Mandai M: PDK2 leads to cisplatin resistance through suppression of
mitochondrial function in ovarian clear cell carcinoma. Cancer Sci.
112:4627–4640. 2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kato N, Sasou S and Motoyama T: Expression
of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors
and endometriosis of the ovary. Mod Pathol. 19:83–89.
2006.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Amano Y, Mandai M, Yamaguchi K, Matsumura
N, Kharma B, Baba T, Abiko K, Hamanishi J, Yoshioka Y and Konishi
I: Metabolic alterations caused by HNF1β expression in ovarian
clear cell carcinoma contribute to cell survival. Oncotarget.
6:26002–26017. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Chandra S, Srinivasan S and Batra J:
Hepatocyte nuclear factor 1 beta: A perspective in cancer. Cancer
Med. 10:1791–1804. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shen H, Fridley BL, Song H, Lawrenson K,
Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, et
al: Epigenetic analysis leads to identification of HNF1B as a
subtype-specific susceptibility gene for ovarian cancer. Nat
Commun. 4(1628)2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Burghaus S, Fasching PA, Häberle L, Rübner
M, Büchner K, Blum S, Engel A, Ekici AB, Hartmann A, Hein A, et al:
Genetic risk factors for ovarian cancer and their role for
endometriosis risk. Gynecol Oncol. 145:142–147. 2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Yamamoto S, Tsuda H, Aida S, Shimazaki H,
Tamai S and Matsubara O: Immunohistochemical detection of
hepatocyte nuclear factor 1beta in ovarian and endometrial
clear-cell adenocarcinomas and nonneoplastic endometrium. Hum
Pathol. 38:1074–1080. 2007.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Lu W, Sun J, Zhou H, Wang F, Zhao C, Li K,
Fan C, Ding G and Wang J: HNF1B inhibits cell proliferation via
repression of SMAD6 expression in prostate cancer. J Cell Mol Med.
24:14539–14548. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ito F, Yoshimoto C, Yamada Y, Sudo T and
Kobayashi H: The HNF-1β-USP28-Claspin pathway upregulates DNA
damage-induced Chk1 activation in ovarian clear cell carcinoma.
Oncotarget. 9:17512–17522. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Suzuki E, Kajita S, Takahashi H, Matsumoto
T, Tsuruta T and Saegusa M: Transcriptional upregulation of HNF-1β
by NF-κB in ovarian clear cell carcinoma modulates susceptibility
to apoptosis through alteration in bcl-2 expression. Lab Invest.
95:962–972. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Preya UH, Woo JH, Choi YS and Choi JH:
Hepatocyte nuclear factor-1 beta protects endometriotic cells
against apoptotic cell death by up-regulating the expression of
antiapoptotic genes. Biol Reprod. 101:686–694. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wendel JRH, Wang X and Hawkins SM: The
endometriotic tumor microenvironment in ovarian cancer. Cancers
(Basel). 10(261)2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Capobianco A and Rovere-Querini P:
Endometriosis, a disease of the macrophage. Front Immunol.
4(9)2013.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Yamada Y, Uchiyama T, Ito F, Kawahara N,
Ogawa K, Obayashi C and Kobayashi H: Clinical significance of M2
macrophages expressing heme oxygenase-1 in malignant transformation
of ovarian endometrioma. Pathol Res Pract. 215:639–643.
2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Ogawa K, Liu T, Kawahara N and Kobayashi
H: Macrophages protect endometriotic cells against oxidative damage
through a cross-talk mechanism. Reprod Sci. 29:2165–2178.
2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Bacci M, Capobianco A, Monno A, Cottone L,
Di Puppo F, Camisa B, Mariani M, Brignole C, Ponzoni M, Ferrari S,
et al: Macrophages are alternatively activated in patients with
endometriosis and required for growth and vascularization of
lesions in a mouse model of disease. Am J Pathol. 175:547–556.
2009.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Colvin EK: Tumor-associated macrophages
contribute to tumor progression in ovarian cancer. Front Oncol.
4(137)2014.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Canet B, Pons C, Espinosa I and Prat J:
CDC42-positive macrophages may prevent malignant transformation of
ovarian endometriosis. Hum Pathol. 43:720–725. 2012.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Guerriero S, Alcazar JL, Coccia ME, Ajossa
S, Scarselli G, Boi M, Gerada M and Melis GB: Complex pelvic mass
as a target of evaluation of vessel distribution by color Doppler
sonography for the diagnosis of adnexal malignancies: Results of a
multicenter European study. J Ultrasound Med. 21:1105–1111.
2002.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Yoshimoto C, Takahama J, Iwabuchi T,
Uchikoshi M, Shigetomi H and Kobayashi H: Transverse relaxation
rate of cyst fluid can predict malignant transformation of ovarian
endometriosis. Magn Reson Med Sci. 16:137–145. 2017.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Matsubara S, Kawahara N, Horie A, Murakami
R, Horikawa N, Sumida D, Wada T, Maehana T, Yamawaki A, Ichikawa M,
et al: Magnetic resonance relaxometry improves the accuracy of
conventional MRI in the diagnosis of endometriosis-associated
ovarian cancer: A case report. Mol Clin Oncol. 11:296–300.
2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Liu T, Sumida D, Wada T, Maehana T,
Yamawaki A, Sugimoto S, Kawahara N, Yoshimoto C and Kobayashi H: A
diagnostic challenge of seromucinous borderline tumor: A case
report. Medicine (Baltimore). 98(e15707)2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Kawahara N, Miyake R, Yamanaka S and
Kobayashi H: A novel predictive tool for discriminating
endometriosis associated ovarian cancer from ovarian endometrioma:
The R2 predictive index. Cancers (Basel). 13(3829)2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kobayashi H, Yamada Y, Kawahara N, Ogawa K
and Yoshimoto C: Modern approaches to noninvasive diagnosis of
malignant transformation of endometriosis. Oncol Lett.
17:1196–1202. 2019.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Molina R, Ojeda B, Filella X, Borras G, Jo
J, Mas E, Lopez JJ and Ballesta A: A prospective study of tumor
markers CA 125 and CA 19.9 in patients with epithelial ovarian
carcinomas. Tumour Biol. 13:278–286. 1992.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Arakawa N, Miyagi E, Nomura A, Morita E,
Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome-based
identification of TFPI2, a novel serum biomarker for detection of
ovarian clear cell adenocarcinoma. J Proteome Res. 12:4340–4350.
2013.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Urban N, Thorpe J, Karlan BY, McIntosh MW,
Palomares MR, Daly MB, Paley P and Drescher CW: Interpretation of
single and serial measures of HE4 and CA125 in asymptomatic women
at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev.
21:2087–2094. 2012.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Zapardiel I, Gorostidi M, Ravaggi A,
Allende MT, Silveira M and Macuks R: Utility of human epididymis
protein 4 serum marker for the detection of adnexal malignancy: A
multicentric prospective study. Eur J Cancer Prev. 26:346–350.
2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Lycke M, Ulfenborg B, Malchau Lauesgaard
J, Kristjansdottir B and Sundfeldt K: Consideration should be given
to smoking, endometriosis, renal function (eGFR) and age when
interpreting CA125 and HE4 in ovarian tumor diagnostics. Clin Chem
Lab Med. 59:1954–1962. 2021.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Blackman A, Mitchell J, Rowswell-Turner R,
Singh R, Kim KK, Eklund E, Skates S, Bast RC, Messerlian G, Miller
MC and Moore RG: Analysis of serum HE4 levels in various histologic
subtypes of epithelial ovarian cancer and other malignant tumors.
Tumour Biol. 43:355–365. 2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Dikmen ZG, Colak A, Dogan P, Tuncer S and
Akbiyik F: Diagnostic performances of CA125, HE4, and ROMA index in
ovarian cancer. Eur J Gynaecol Oncol. 36:457–462. 2015.PubMed/NCBI
|
|
82
|
Wang Z, Tao X and Ying C: CPH-I and HE4
Are more favorable than CA125 in differentiating borderline ovarian
tumors from epithelial ovarian cancer at early stages. Dis Markers.
2019(6241743)2019.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Arakawa N, Kobayashi H, Yonemoto N,
Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y,
Hirahara F, et al: Clinical significance of tissue factor pathway
inhibitor 2, a serum biomarker candidate for ovarian clear cell
carcinoma. PLoS One. 11(e0165609)2016.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Miyagi E, Arakawa N, Sakamaki K, Yokota
NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y,
Kasamatsu Y, et al: Validation of tissue factor pathway inhibitor 2
as a specific biomarker for preoperative prediction of clear cell
carcinoma of the ovary. Int J Clin Oncol. 26:1336–1344.
2021.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Revathidevi S, Nakaoka H, Suda K, Fujito
N, Munirajan AK, Yoshihara K, Enomoto T and Inoue I: APOBEC
mediated mutagenesis drives genomic heterogeneity in endometriosis.
J Hum Genet. 67:323–329. 2022.PubMed/NCBI View Article : Google Scholar
|
